AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties

AnaptysBio

21/09/2026 21:26

Overview
US royalty manager's Q2 collaboration revenue rose yr/yr, driven by higher Jemperli royalties
Net income from continuing operations surged, mainly due to a large tax benefit
As of June 30, company has not repurchased shares under its $100 mln buyback plan; litigation judgement expected Q4 2026 or Q1 2027

Outlook
Company anticipates FDA approval of Jemperli in rectal cancer by February 2027
Anaptys expects FDA approval of Quimilza in GPP in December 2026
Company expects to achieve >$390 mln in annualized Jemperli royalties as early as 2029

Result Drivers
JEMPERLI ROYALTIES - Higher Jemperli royalties drove collaboration revenue growth
TAX BENEFIT - Net income surged due to release of valuation allowance on deferred tax assets after company separation
LEGAL COSTS - Higher general and administrative expenses mainly due to legal costs for company separation and GSK/Tesaro litigation

Company press release: ID:nGNXbdmb8S

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$27.49 mln
 
Q2 Net Income
 
$183.88 mln
 
Q2 Income From Operations
 
$14.15 mln
 
Q2 Operating Expenses
 
$13.34 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AnaptysBio, Inc. is $85.50, about 54.9% above its September 18 closing price of $55.20

Reuters Recommended Reads
Sept 21 - Drug developer ADARx seeks $1.74 billion valuation in US IPO
Sept 18 - Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Sept 21 - Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)